Harrow, Inc. (NASDAQ:HROW) Stock Rated “Hold” by Sell-Side Analysts

Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) have received an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $66.20.

A number of brokerages have recently weighed in on HROW. Weiss Ratings upgraded shares of Harrow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, November 13th. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. BTIG Research reiterated a “buy” rating and issued a $63.00 target price on shares of Harrow in a research note on Wednesday, November 11th. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 3rd. Finally, Leerink Partners assumed coverage on shares of Harrow in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock.

Get Our Latest Report on Harrow

Institutional Investors Weigh In On Harrow

Several hedge funds and other institutional investors have recently made changes to their positions in HROW. BlackRock Inc. acquired a new stake in shares of Harrow in the second quarter valued at about $116,373,000. Luxor Capital Group LP increased its stake in shares of Harrow by 22.0% in the first quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock worth $39,470,000 after purchasing an additional 201,859 shares during the period. Bamco Inc. NY acquired a new position in shares of Harrow during the 2nd quarter worth about $34,373,000. Jupiter Topco LLC acquired a new position in shares of Harrow during the 2nd quarter worth about $24,596,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Harrow by 56.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after purchasing an additional 208,972 shares during the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Stock Up 8.9%

Shares of Harrow stock opened at $32.16 on Thursday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -41.23 and a beta of 0.18. The company has a quick ratio of 2.12, a current ratio of 2.29 and a debt-to-equity ratio of 10.15. The stock has a 50 day moving average price of $30.31 and a two-hundred day moving average price of $37.35. Harrow has a 12-month low of $25.76 and a 12-month high of $54.85.

Harrow (NASDAQ:HROW – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.19 by $0.06. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. The company had revenue of $99.30 million for the quarter, compared to the consensus estimate of $98.59 million. Equities analysts expect that Harrow will post -0.50 earnings per share for the current year.

Harrow Company Profile

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Featured Stories

Analyst Recommendations for Harrow (NASDAQ:HROW)

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.